Business
Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio
- Lantern Pharma's A.I. and machine learning platform, RADR®, aided in the identification of additional pediatric cancers where Lantern's portfolio of drug
About this update from Lantern Pharma Inc.
[{"type":"text","content":"- Lantern Pharma's A.I. and machine learning platform, RADR®, aided in the identification of additional pediatric cancers where Lantern's portfolio of drug candidates can be leveraged.\n - The research will initially focus on advancing the development of Lantern Pharma's drug candidate, LP-184, into additional childhood cancer indications using models developed by Dr. Peter Houghton, Ph.D. at the GCCRI.\n - Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers.\n\n\nDALLAS, Feb. 15, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a Dallas-based clinical stage biopharmaceutical company using its proprietary artificial intelligence (\"A.I.\") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it is expanding opportunities for its portfolio of drug candidates and A.I. drug discovery platform into additional rare pediatric cancers through a collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at the University of Texas Health Science Center at San Antonio (UTHSCSA). GCCRI is one of only two research institutions in the United States focused exclusively on pediatric cancer research and therapy development.\n\n \n \n \n \n \n \n\n \nThe research collaboration will focus on further validating findings from RADR® regarding the effectiveness of Lantern's LP-184 and LP-284 in genomically-defined pediatric cancers, including several without any effective therapeutic approach. The collaboration will initially leverage GCCRI's pediatric tumor research models and knowledge base to advance Lantern's drug candidate, LP-184, for the treatment of rare pediatric cancers including rhabdomyosarcoma, Ewing sarcoma, MRT (malignant rhabdoid tumor), Wilms tumor, and ATRT (atypical teratoid rhabdoid tumor). The National Cancer Institute describes several of these tumor types to have limited treatment options available, and many of these tumors continue to progress after standard therapy. \n\"Transforming the pace at which we develop new therapies for pediatric and rare cancers requires that we make constant use of data, advanced approaches and models, and machine learning to maximize the therapeutic potential ...